The Canadian medical agency tasked with tracking and regulating the use and production of cannabis in the country announced new numbers on Monday (July 9) in terms of medical patients of the drug.

As part of the market information Health Canada tracks and publishes for cannabis, the agency now offers data on a monthly basis for its fiscal quarters, with the most recent one being January to March.

Based on the data, patient registration under the Access to Cannabis for Medical Purposes Regulations (ACMPR) program has continued to increase. At the end of March 2018, the fiscal fourth quarter for Health Canada, data showed a total number of patient registrations of 296,702.

According to cannabis analyst with 420 Investor Alan Brochstein, the growth last quarter represents quarterly growth of 10.1 percent and annual growth of 79.9 percent.

Brochstein called the increment in legal cannabis patients “robust” but highlighted it was the slowest quarterly growth since the origin of the program. He said these figures represent a maturation of the medical cannabis program and “perhaps some hesitancy among potential patients who will just wait for legalization.

Cannabis oils continue market dominance in legal medical landscape

The federal agency also offered an update on the amount of legal cannabis patients had access to during the most recent fiscal quarter.

Cannabis oils continued its growth path while dried flower remained steady with 6,610 kilograms sold during the fourth fiscal quarter. Oils amounted to 10,326 kilograms, an 11 percent increase from the previous quarter according to Brochstein.

During the fiscal 2017-2018 year, Health Canada reported 33,463 kilograms of cannabis oil sold to patients, while the amount of dried flower sold during the fiscal year was 24,753 kilograms.

Licensed producers (LP) of cannabis in Canada reported a total saved inventory worth 44,179 kilograms of dried cannabis and 15,727 litres at the end of March.

Investor takeaway

Despite the limited offerings of legal cannabis product for consumers at the time of this data, investors are able to see the demand for cannabis oils surpases dried flower in the medical space as consumers seek more variety for treatments.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less